Department of Gynecologic Oncology, Saitama Medical School International Medical Center, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan.
Curr Oncol Rep. 2013 Jun;15(3):197-200. doi: 10.1007/s11912-013-0313-9.
The aim of neoadjuvant chemotherapy is to reduce the tumor volume or spread of the disease before the main treatment, and it could possibly make the main procedures easier or less invasive. Although the standard therapeutic strategy for advanced ovarian cancer is a maximum primary debulking surgery followed by chemotherapy, a European Organisation for Research and Treatment of Cancer (EORTC) prospective randomized trial demonstrated that neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to the standard procedure. This study raised a number of controversies, particularly regarding the quality of debulking surgery. To solve the questions, we need to wait for the results of two additional ongoing randomized trials. However, the results of those two trials must be carefully assessed, because the quality of debulking surgery would significantly affect survival, and may make the interpretation of the trial results more confusing and difficult.
新辅助化疗的目的是在主要治疗前缩小肿瘤体积或减少疾病的扩散，这可能使主要治疗过程更容易或创伤更小。虽然晚期卵巢癌的标准治疗策略是最大限度的初次肿瘤细胞减灭术，然后进行化疗，但欧洲癌症研究与治疗组织（EORTC）的一项前瞻性随机试验表明，新辅助化疗后间隔肿瘤细胞减灭术并不逊于标准程序。这项研究引发了一些争议，特别是关于肿瘤细胞减灭术的质量。为了解决这些问题，我们需要等待另外两项正在进行的随机试验的结果。然而，这两项试验的结果必须仔细评估，因为肿瘤细胞减灭术的质量会显著影响生存，并且可能使试验结果的解释更加混乱和困难。
